Source 1review1998Leukemia & lymphoma/Leukemia and lymphoma
Toolkit/FasL-neutralizing monoclonal antibody
FasL-neutralizing monoclonal antibody
Taxonomy: Technique Branch / Method. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
These target T cells were protected from programmed cell death by ... preincubation ... of myeloma cells with a FasL-neutralizing mAb.
Usefulness & Problems
Why this is useful
This monoclonal antibody is used to neutralize FasL on myeloma cells before coculture. In the abstract, that intervention protects Fas-sensitive target T cells from death.; neutralizing FasL on effector cells; testing whether apoptosis depends on FasL-mediated signaling
Source:
This monoclonal antibody is used to neutralize FasL on myeloma cells before coculture. In the abstract, that intervention protects Fas-sensitive target T cells from death.
Source:
neutralizing FasL on effector cells
Source:
testing whether apoptosis depends on FasL-mediated signaling
Problem solved
It helps determine whether the effector-cell ligand, rather than another mechanism, is responsible for the observed apoptosis.; provides a ligand-side intervention to test causality in Fas/FasL-dependent killing
Source:
It helps determine whether the effector-cell ligand, rather than another mechanism, is responsible for the observed apoptosis.
Source:
provides a ligand-side intervention to test causality in Fas/FasL-dependent killing
Problem links
provides a ligand-side intervention to test causality in Fas/FasL-dependent killing
LiteratureIt helps determine whether the effector-cell ligand, rather than another mechanism, is responsible for the observed apoptosis.
Source:
It helps determine whether the effector-cell ligand, rather than another mechanism, is responsible for the observed apoptosis.
Taxonomy & Function
Primary hierarchy
Technique Branch
Method: A concrete measurement method used to characterize an engineered system.
Techniques
Functional AssayTarget processes
signalingImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: sensor
It requires a FasL-neutralizing antibody and a coculture assay in which FasL-expressing cells are tested for killing activity.; requires preincubation of myeloma cells; use is limited to contexts where FasL expression is present and functionally relevant
The abstract does not provide details on reagent identity, potency, or use outside the reported in vitro setting.; the abstract does not specify clone, epitope, or broader validation details
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Blocking Fas on target T cells or neutralizing FasL on myeloma cells protects target T cells from programmed cell death, supporting Fas/FasL-mediated signaling as the effector pathway in the described myeloma system.
Overexpression of the caspase inhibitor CrmA protected target T cells from killing by myeloma cells, supporting assignment of the killing mechanism to Fas/FasL-mediated signaling.
Approval Evidence
1 source1 linked approval claimfirst-pass slug fasl-neutralizing-monoclonal-antibody
These target T cells were protected from programmed cell death by ... preincubation ... of myeloma cells with a FasL-neutralizing mAb.
Source:
mechanistic interference summarysupports
Blocking Fas on target T cells or neutralizing FasL on myeloma cells protects target T cells from programmed cell death, supporting Fas/FasL-mediated signaling as the effector pathway in the described myeloma system.
Source:
Comparisons
Source-stated alternatives
The abstract also mentions Fas-blocking monoclonal antibody and CrmA overexpression as alternative pathway-dissection tools.
Source:
The abstract also mentions Fas-blocking monoclonal antibody and CrmA overexpression as alternative pathway-dissection tools.
Source-backed strengths
reported to protect target T cells from programmed cell death in the described assay
Source:
reported to protect target T cells from programmed cell death in the described assay
Compared with CrmA overexpression
The abstract also mentions Fas-blocking monoclonal antibody and CrmA overexpression as alternative pathway-dissection tools.
Shared frame: source-stated alternative in extracted literature
Strengths here: reported to protect target T cells from programmed cell death in the described assay.
Relative tradeoffs: the abstract does not specify clone, epitope, or broader validation details.
Source:
The abstract also mentions Fas-blocking monoclonal antibody and CrmA overexpression as alternative pathway-dissection tools.
Compared with Fas-blocking monoclonal antibody
The abstract also mentions Fas-blocking monoclonal antibody and CrmA overexpression as alternative pathway-dissection tools.
Shared frame: source-stated alternative in extracted literature
Strengths here: reported to protect target T cells from programmed cell death in the described assay.
Relative tradeoffs: the abstract does not specify clone, epitope, or broader validation details.
Source:
The abstract also mentions Fas-blocking monoclonal antibody and CrmA overexpression as alternative pathway-dissection tools.
Ranked Citations
- 1.